Pharma Focus Asia

Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition

Monday, June 19, 2017

Intrexon Corporation, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced that it has completed the acquisition of GenVec, Inc., a clinical-stage biopharmaceutical company and pioneer in the development of AdenoVerse™ gene delivery technology platform.

With the addition of GenVec's AdenoVerse™ technology and accomplished team, Intrexon intends to create the next generation of adenoviral (AdV) delivery with significantly higher payload capacity that exceeds 30kb, as compared to current viral delivery methods ranging from 4.5kb – 9kb, through a scalable manufacturing platform utilizing helper-dependent adenovirus. This expanded capacity will further advance the field of gene-based medicine by enabling delivery of multiple therapeutic effectors that is not possible with current viral delivery systems.

Additionally Intrexon's RheoSwitch Therapeutic System® platform combined with GenVec's AdV-based technology is projected to accelerate its ability to develop cutting-edge gene therapies that regulate in vivo expression of one or several therapeutic effectors.  GenVec's selection of vector origins and serotypes as well as know-how in specifying cellular and tissue targets is expected to expedite the design and production of vectors that complement Intrexon's multigene programming and keen focus on safety with limited off-target effect.

"GenVec's AdenoVerse™ platform is highly adaptable and can be customized to develop applications for regenerative and cell therapeutics as well as gene and antigen delivery strategies," commented Thomas D. Reed, Ph.D., Intrexon's Chief Science Officer. "The breadth of GenVec's natural and engineered adenovector serotypes displaying valuable targeted tissue specificity, when combined with our RheoSwitch Therapeutic System® gene switch offer significant potential for cutting-edge in vivo multi-gene therapies."

Douglas E. Brough, Ph.D., GenVec's Chief Scientific Officer stated, "We look forward to combining our research and drug development team with Intrexon to advance groundbreaking in vivo therapeutics. Together we expect to develop a next-generation delivery platform capable of increasing payload capacity far beyond that of other viral methods for application to Intrexon's current and future health programs."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024